ArticleOncology research2025

Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam.

Khanh Toan Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.